|

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

RECRUITINGSponsored by AbbVie
Actively Recruiting
SponsorAbbVie
Started2026-02-27
Est. completion2026-06
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07419347

Summary

The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P).
* Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)
* Is concomitantly on one or more prescription medications or illicit drugs.

Exclusion Criteria:

* Treated with DAAs other than G/P.
* History of decompensated cirrhosis.
* Had Hepatitis-B virus (HBV) infection.
* Had hepatocellular carcinoma (HCC).

Conditions2

Hepatitis C Virus (HCV)Liver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.